Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)

The summary for the Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional): This Funding Opportunity Announcement (FOA) encourages applications to NIA's Small Business Technology Transfer Research (STTR)program to conduct research leading to the development of innovative products and/or services that may advance progress in preventing and treating Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD) and/or caring for and treating AD/ADRD patients.

Federal Grant Title:	Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAS-18-188
Type of Funding:	Grant
CFDA Numbers:	93.866
CFDA Descriptions:	Information not provided
Current Application Deadline:	September 5th, 2019
Original Application Deadline:	September 5th, 2019
Posted Date:	November 28th, 2017
Creation Date:	November 28th, 2017
Archive Date:	October 11th, 2019
Total Program Funding:	$5,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:	10
Cost Sharing or Matching:	No
Last Updated:	November 28th, 2017

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAS-18-188.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Artificial Intelligence and Technology Collaboratory (P30 Clinical Trial Optional); • Artificial Intelligence and Technology Collaboratory Coordinating Center (U24 Clinical Tri...; • Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional); • NIA Expanding Research in AD/ADRD (ERA) Summer Research Education Program (R25 Independent...; • NIA Expanding Research in AD/ADRD (ERA) Postbaccalaureate Research Education Program (R25 ...; • Technological Enhancements and Archiving for Surveys of the Elderly: SBIR (R43/44) Initiat...; • Technological Enhancements and Archiving for Surveys of the Elderly: STTR (R41/42) Initiat...; • Technology and Aging: NIA Small Business Technology Transfer Program Initiative (STTR [R41...
More Grants from the National Institutes of Health: • NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional); • Single Source Renewal for the Continuation of the Liver Cirrhosis Network: Scientific and ...; • NIGMS Institutional Biomedical Undergraduate Research Training (BURT) Program (T34); • Limited Competition: Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic ...; • Maximizing Investigators' Research Award (MIRA) (R35 - Clinical Trial Optional)